Payment overview · 2025
General Payments
$291.00
11 reported records · 5 companies
Healthcare provider profile · identity verified
Brian D. Cassetta, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HORSEHEADS, NY · NPI 1336116037
Verified facts
What the public records show
CMS Open Payments records show Brian D. Cassetta, MD received $291.00 in general payments during 2025 across 11 reported records.
Exact Sciences Corporation accounted for 34.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 310 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $98.79 | 34.0% | 2 | 2025 |
| SPR Therapeutics, Inc | Unresolved — no canonical attribution shown | $67.81 | 23.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.76 | 19.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.18 | 12.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.46 | 10.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $291.00 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $85.06 | 1 | 2025 |
Source payment records
|
|||||
| SPRINT PNS System Normalized: sprint pns system |
Device | SPR Therapeutics, Inc | $67.81 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.76 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.18 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.46 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.46 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
310 | 64 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 740 | 221 |
| Levothyroxine Sodium | Levothyroxine Sodium | 596 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 569 | 142 |
| Atorvastatin Calcium | Atorvastatin Calcium | 554 | 151 |
| Omeprazole | Omeprazole | 545 | 144 |
| Metoprolol Succinate | Metoprolol Succinate | 536 | 155 |
| Lisinopril | Lisinopril | 457 | 120 |
| Pantoprazole Sodium | Pantoprazole Sodium | 430 | 100 |
| Furosemide | Furosemide | 347 | 79 |
| Escitalopram Oxalate | Escitalopram Oxalate | 329 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 328 | 105 |
| Eliquis | Apixaban | 310 | 64 |
| Metformin Hcl | Metformin Hcl | 307 | 86 |
| Gabapentin | Gabapentin | 232 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 228 | 61 |
| Losartan Potassium | Losartan Potassium | 221 | 66 |
| Fluticasone Propionate | Fluticasone Propionate | 188 | 60 |
| Allopurinol | Allopurinol | 184 | 50 |
| Mirtazapine | Mirtazapine | 183 | 44 |
| Valsartan | Valsartan | 183 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 179 | 72 |
| Prednisone | Prednisone | 179 | 93 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 45 |
| Montelukast Sodium | Montelukast Sodium | 160 | 38 |
| Famotidine | Famotidine | 157 | 48 |
| Spironolactone | Spironolactone | 154 | 38 |
| Pregabalin | Pregabalin | 143 | 32 |
| Alprazolam | Alprazolam | 140 | 43 |
| Sertraline Hcl | Sertraline Hcl | 139 | 30 |
| Bupropion Xl | Bupropion Hcl | 128 | 34 |
| Tramadol Hcl | Tramadol Hcl | 125 | 50 |
| Trazodone Hcl | Trazodone Hcl | 125 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 25 |
| Jardiance | Empagliflozin | 115 | 26 |
| Celecoxib | Celecoxib | 114 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 28 |
| Potassium Chloride | Potassium Chloride | 110 | 29 |
| Donepezil Hcl | Donepezil Hcl | 101 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 100 | 19 |
| Simvastatin | Simvastatin | 100 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 30 |
| Ezetimibe | Ezetimibe | 98 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 98 | 26 |
| Amoxicillin | Amoxicillin | 90 | 71 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 22 |
| Carvedilol | Carvedilol | 85 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 31 |
| Torsemide | Torsemide | 85 | 25 |
| Synthroid | Levothyroxine Sodium | 84 | 22 |
| Glipizide Er | Glipizide | 82 | 19 |
| Clonazepam | Clonazepam | 81 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 81 | 21 |
| Azithromycin | Azithromycin | 79 | 58 |
| Ozempic | Semaglutide | 79 | 20 |
| Meloxicam | Meloxicam | 76 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 76 | 11 |
| Buspirone Hcl | Buspirone Hcl | 74 | 19 |
| Finasteride | Finasteride | 74 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 73 | 21 |
| Atenolol | Atenolol | 72 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 71 | 50 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 17 |
| Xarelto | Rivaroxaban | 61 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | 20 |
| Metformin Hcl Er | Metformin Hcl | 59 | 14 |
| Alendronate Sodium | Alendronate Sodium | 58 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 11 |
| Ramipril | Ramipril | 57 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 55 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 49 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 11 |
| Baclofen | Baclofen | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 44 | 18 |
| Nystatin | Nystatin | 44 | 17 |
| Sucralfate | Sucralfate | 44 | 15 |
| Glimepiride | Glimepiride | 43 | 13 |
| Ondansetron Odt | Ondansetron | 43 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Sotalol | Sotalol Hcl | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 33 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 22 |
| Diazepam | Diazepam | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Nadolol | Nadolol | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 26 |
| Fluconazole | Fluconazole | 27 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 22 |
| Colchicine | Colchicine | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 24 |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 21 |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 12 |
| Tadalafil | Tadalafil | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $291.00 · 11 records | Exact Sciences Corporation | Cologuard Collection Kit, NURTEC ODT, Ozempic, SPRINT PNS System, The Cologuard Plus Collection Kit, VRAYLAR, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error